Long-term outcomes of half-dose photodynamic therapy for chronic central serous chorioretinopathy.

Long-term outcomes of half-dose photodynamic therapy for chronic central serous chorioretinopathy. - Examination of the long-term outcomes of hPDT for CSC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061197

Enrollment

Registered

2026-04-08

Start date

2026-04-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic central serous chorioretinopathy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who underwent treatment with half-dose photodynamic therapy between January 1, 2015 and December 31, 2020.

Exclusion criteria

Exclusion criteria: Patients with a history of intravitreal injection or vitrectomy.

Design outcomes

Primary

Measure	Time frame
Recurrence rate	—

Secondary

Measure	Time frame
Whether or not atrophy is present, and whether or not additional treatment is necessary.Changes in visual acuity and retinal thickness	—

Countries

Japan

Contacts

Public ContactKazuma Tamura

Nagoya University Hospital ophthalmology

tamura.kazuma.g4@f.mail.nagoya-u.ac.jp08045529195

Outcome results